Last reviewed · How we verify
NCT05416827
Evaluation of Intraoperative Slow-release Dexamethasone Implant for Epiretinal Membrane
NA trial testing slow-release dexamethasone implant in Epiretinal Membrane in 30 participants. Status unknown.
15 September 2022
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 June 2022 |
| Primary completion | 15 September 2022 |
| Estimated completion | 15 September 2022 |
Drugs / interventions tested
- slow-release dexamethasone implant
Conditions studied
- Epiretinal Membrane — all drugs for Epiretinal Membrane →
Sponsor
Peking University People's Hospital
Who can join
18 and older, any sex, with Epiretinal Membrane. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Epiretinal membrane (ERM) is a commonly encountered vitreoretinal interface anomaly with a prevalence of approximately 10% in the adult population. It is often treated with pars plana vitrectomy (PPV) and membrane peeling when symptomatic. PPV is generally successful at improving visual acuity (VA) and/or metamorphopsia. At times, however, visual recovery can be hindered by macular edema in the post-vitrectomy period. Ozurdex can accelerate the resorption of intraretinal edema and hasten the improvement in the visual acuity. It has been shown to facilitate fluid absorption by both stimulating endogenous adenosine signaling in Muller cells and by down regulating vascular endothelial growth factor production. So, this study aim to investigate the efficacy of Ozurdex implant after PPV in epiretinal membrane eyes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex) in epiretinal membrane peeling surgery: a prospective randomized controlled trial.
Li S, Zeng Q, Zhu L, Liu W, et al · · 2023 · cited 3× · PMID 37727387 · DOI 10.3389/fphar.2023.1219861
Verify or expand the search:
- PubMed search for NCT05416827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of slow-release dexamethasone implant
Trials testing the same drug.
- NCT05415826 — Ozurdex in Reducing PVR After Vitreotomy in PDR · NA · unknown
Other recruiting trials for Epiretinal Membrane
Currently open trials in the same condition.
- NCT07019896 — Minimal Vitrectomy Surgery for Epiretinal Membrane · NA · recruiting
- NCT06719739 — Functional IOL Implantation in Patients With Epiretinal Membrane · NA · recruiting
- NCT06948851 — New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes · active not recruiting
- NCT05145491 — Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM · NA · recruiting
- NCT04306718 — Cultivation of Hyalocytes From ILM and ERM Samples: a Pilot Study · NA · active not recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05416827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 13 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05416827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing